This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Guillaume T, Rubinstein DB, Symann M . Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 1998; 92: 1471–1490.
Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15: 1143–1238.
Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850–854.
Antin JH, Guinan EC, Avigan D, Soiffer RJ, Joyce RM, Martin VJ et al. Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 213–222.
Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Fang HB, Cai L et al. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood 2011; 117: 788–797.
Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume K et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002; 347: 26–34.
Rapoport AP, Stadtmauer EA, Aqui N, Badros A, Cotte J, Chrisley L et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 2005; 11: 1230–1237.
Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res 2013; 19: 3640–3648.
Brody JD, Goldstein MJ, Czerwinski DK, Levy R . Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. Blood 2009; 113: 85–94.
Prevnar 13 prescribing information. http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm201669.pdf.
Szu SC, Lee CJ, Parke JC Jr, Schiffman G, Henrichsen J, Austrian R et al. Cross-immunogenicity of pneumococcal group 9 capsular polysaccharides in adult volunteers. Infect Immun 1982; 35: 777–782.
Lendvai N, Cohen AD, Cho HJ . Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. Bone Marrow Transplant 2015; 50: 770–780.
Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011; 17: 1290–1297.
Acknowledgements
This work was supported in part by the Cancer Center Support Grant P30 CA076292 from the National Cancer Institute.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Locke, F., Menges, M., Nishihori, T. et al. Boosting humoral and cellular immunity to pneumococcus by vaccination before and just after autologous transplant for myeloma. Bone Marrow Transplant 51, 291–294 (2016). https://doi.org/10.1038/bmt.2015.239
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2015.239
This article is cited by
-
Pneumococcal-13-valent-CRM197 vaccine conjugate
Reactions Weekly (2016)